Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIAL
Lisa M. van Lierop, Frank Hoentjen(Radboud University Nijmegen), Adriaan A. van Bodegraven(Maastricht University Medical Centre), Bas Oldenburg(University Medical Center Utrecht), Annemarie C. de Vries(Erasmus MC), Zlatan Mujagic(Maastricht University Medical Centre), Rosalie C. Mallant–Hent, Alexander Bodelier(Amphia Ziekenhuis), Sita Jansen(Reinier de Graaf Hospital), Frank H.J. Wolfhagen(Albert Schweitzer Ziekenhuis), Henri Braat(Medisch Spectrum Twente), J van der Woude(Erasmus University Rotterdam), Maurice Lutgens(Elisabeth-TweeSteden Ziekenhuis), Dirk J. de Jong(Radboud University Nijmegen), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Pieter ter Borg(Ikazia Ziekenhuis), Paul J. Boekema(Radboud University Nijmegen), Nathan den Broeder(Radboud University Nijmegen), F. A. R. Jansen, Rachel West(Sint Franciscus Gasthuis), Jeroen M. Jansen(OLVG), Adrianus Tan(Canisius-Wilhelmina Ziekenhuis), Nanne K.H. de Boer, Ingrid Gisbertz(Ziekenhuis Bernhoven), Andrea V. Meulen - De Jong
Cited by 0
Related Papers
Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity
|Science|2016|2k
Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases
|Nature Genetics|2019|1.6k
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Genome-wide association identifies multiple ulcerative colitis susceptibility loci
|Nature Genetics|2010|680
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478